Marina Biotech Provides Business Update CITY OF INDUSTRY,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
62
Marina Biotech Provides Business Update

CITY OF INDUSTRY, CA--(Marketwired - Apr 5, 2017) -    Marina Biotech, Inc. ( OTCQB : MRNA ), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, provided today a corporate update to investors, following the filing of its 10-K for the year ended December 31, 2016 with the SEC.

Joseph Ramelli, CEO of Marina Biotech, stated, "Since announcing Marina Biotech's merger with IthenaPharma just six months ago, we have moved quickly to assemble an operational team and implement a strategy to advance our pipeline of combination therapies and novel oligotherapeutics. We are driven by our commitment to improve the lives of patients by delivering novel therapies that we believe will improve outcomes while reducing the undesirable side effects of many current therapies."

"In the past several weeks, we announced preclinical and clinical data at several healthcare conferences for our two arthritis pain/hypertension drug candidates, IT-102 and IT-103. This data further supports the development of IT-102 and IT-103, not only for combined hypertensive/pain, but also for the treatment of cancers such as FAP and colorectal cancer. We also announced the signing of a definitive agreement with Windlas Healthcare to manufacture the IT-102 CTM batch for our pivotal phase III trial to be initiated in the first quarter of 2018."

"We also announced findings of the START-FAP (Safety and Tolerability of an RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial at the Biotech Showcase 2017 and Society of Toxicology's 56th Annual Meeting. START-FAP evaluated CEQ508, tkRNAi against beta-catenin, for the treatment of FAP and achieved primary and secondary end-points for safety and efficacy in knocking down beta-catenin in FAP patients. As the only oral delivery platform for oligotherapeutics, we are excited to continue to develop CEQ508 as a therapy for Familial Adenomatous Polyposis (FAP), as well as expansion of the platform to other indications."

"In addition to developing our pipeline of therapeutics, we are positioned to effectively tap into the significant partnership opportunities for our SMARTICLES and tkRNAi delivery platforms. In early-February, we announced a licensing agreement with LipoMedics through which Marina Biotech could receive up to $90 million in success-based milestone payments. We have obtained another line of credit with Autotelic Inc. to further extend the runway for the commercialization of IT-102 and IT-103. With the additional line of credit, definitive manufacturing agreement and strong clinical data findings, Marina is poised for execution going forward and prepared to support near term commercialization of its pipeline," concluded Mr. Ramelli.

Recent Clinical and Corporate Highlights:

  • Late Breaking poster for CEQ508 at the Society of Toxicology 56 th Annual Meeting The poster outlines a dose escalating Phase I trial conducted with daily, oral administration of CEQ508 over 28 days to FAP patients. The clinical results continue to prove that the Company's proprietary tkRNAi delivery platform is a safe and effective oral delivery of siRNA.
  • Updated findings of the START-FAP trial at Biotech Showcase 2016 Marina provided updated findings of the START-FAP having achieved primary and secondary end-points for safety and efficacy in knocking down beta-catenin in FAP patients.
  • Retrospective patient level data for two late stage arthritis pain / hypertension drug candidates, IT-102 and IT-103 This is a retrospective study that uses two patient level data sources over a three-year period to demonstrate suppression of celecoxib drug induced edema by IT-102 and IT-103. The data were presented at the 7 th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus in Cannes, France on March 2-5, 2017. These FDCs are being developed as next generation Celecoxib -- Celecoxib without Celecoxib drug-induced edema -- as inhibitor of the beta-catenin/COX-2 axis for the treatment of pain, arthritis, and cancers such as FAP and CRC. 
  • Preclinical and clinical data supporting the use of IT-102 and IT-103 as novel anticancer agents The synergy between celecoxib and lisinopril/olmesartan (IT-102/IT-103) along with its safety were presented at Endocrine Society Annual Meeting at Orange County Convention Center, Orlando, FL and the American Association for Cancer Research Annual Meeting in Washington, DC. IT-102 and IT-103 suppressed both the COX-2 tumor pathway and the vascular resistance of solid tumor to achieve suppression of tumor growth and metastasis.
  • License agreement for SMARTICLES The Company entered into a license agreement with Lipomedics regarding its SMARTICLES platform for the delivery of nanoparticles, including small molecules, peptides, proteins and biologics. This is the first agreement in which SMARTICLES technologies have been licensed in connection with nanoparticles delivering small molecules, peptides, proteins and biologics. Under terms of the agreement, Marina could receive up to $90 million in success based milestones.
  • Manufacturing agreement for IT-102 FDC bi-layer tablet with Windlas Healthcare Limited Marina selected Windlas Healthcare for the manufacturing of the FDC bi-layer tablets, a stringent FDA cGMP process, which Windlas has the expertise necessary to complete. 
  • Secured line of credit in November 2016, and expanded the line in April 2017 Marina secured a $540,000 line of credit through its Chairman, Dr. Vuong Trieu. The Company has drawn down an aggregate of $250,000 under the line as of December 31, 2016. On April 4, 2017, Marina expanded the line of credit with Dr. Trieu for an additional $500,000. 
  • Completed merger with IThenaPharma Marina merged with IThenaPharma to advance its development and commercialization of combination products for pain, arthritis, hypertension, and cancer.
  • Enhancing Marina's executive management team with key hires:
    • Dr. Seymour Fein appointed as Chief Medical Officer
    • Larn Hwang, Ph.D. appointed as Chief Scientific Officer
    • Mihir Munsif appointed as Chief Operating Officer

Financial Update: On March 31, 2017, the Company filed its 10-K with the SEC, which can be accessed on the Company's website (click here) .

About Marina Biotech Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 -- next generation celecoxib -- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com .

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to successfully integrate its business operations with those of IthenaPharma; (ii) the ability of Marina Biotech to obtain funding to support its clinical development; (iii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iv) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (v) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (vi) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

Investor Contact Garth Russell / Allison Soss KCSA Strategic Communications Phone: (212) 896-1250 / (212) 896-1267 Email: Email Contact / Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 138

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 84

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 162

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 49

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 195

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 103

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 104

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Why Investors Are Making Bold Moves with Dell Technologies

Updated Category News Views 178

Investors Show Confidence in Dell Technologies In recent trading sessions, significant investors have adopted a bullish approach to Dell Technologies (NYSE: DELL). Such movements usually signal investor confidence and the possibility of future price movements. Interestingly, options trading data we've analyzed indicates that this activity stemmed from large transactions,...

Continue Reading
Community Heritage Financial Strengthens Capital Position with Debt Offering

Updated Category News Views 78

Community Heritage Financial Completes Subordinated Debt Offering Community Heritage Financial, Inc. (OTC PK: CMHF), parent company of Middletown Valley Bank, has successfully executed a private placement of subordinated debt, amounting to a substantial $12.1 million. This offering of 6.75% Fixed-to-Floating Rate Subordinated Notes, due 2034, reflects the Company’s...

Continue Reading
Evolent Health Poised for Growth Amid Humana Challenges

Updated Category News Views 185

Understanding Evolent Health's Market Position Recently, analysts at Barclays have reaffirmed their positive outlook on Evolent Health (NYSE: EVH), maintaining an Overweight rating and a price target of $39.00. This confidence comes in light of discussions surrounding the impacts of Humana's recent struggles with Medicare Star ratings. The management team at Evolent,...

Continue Reading
Caracole Teams with Centric PLM for Seamless Growth

Updated Category News Views 31

Revolutionizing the Luxury Furniture Game In the world of luxury furnishings, where every curve and finish sends a message, Caracole is making a bold move to streamline its operations. They're throwing the confetti for Centric PLM, a platform that's set to oust the scattered chaos of spreadsheets and emails. And let me tell you, for any investor eyeing the luxury home...

Continue Reading
RaySearch Laboratories: Exciting Year-End Presentation Ahead

Updated Category News Views 105

Join Us for RaySearch Laboratories' Year-End Report Presentation Analysts, investors, and media representatives are cordially invited to a detailed presentation focused on RaySearch Laboratories' Year-end report for the year 2024. Details of the Presentation Set for February 21, 2025, at 10:00 AM CET, the report will be made accessible to attendees starting at 07:45 AM on...

Continue Reading